Naringenin inhibits NG‑nitro‑L‑arginine methyl ester‑induced hypertensive left ventricular hypertrophy by decreasing angiotensin‑converting enzyme 1 expression

Gao,Yanxiang; Wang,Zhizhi; Zhang,Yayun; Liu,Yuting; Wang,Shanshan; Sun,Weiliang; Guo,Jing; Yu,Changan; Wang,Yong; Kong,Wei; Zheng,Jingang

doi:10.3892/etm.2018.6258

Naringenin inhibits NG‑nitro‑L‑arginine methyl ester‑induced hypertensive left ventricular hypertrophy by decreasing angiotensin‑converting enzyme 1 expression

Authors:
- Yanxiang Gao
- Zhizhi Wang
- Yayun Zhang
- Yuting Liu
- Shanshan Wang
- Weiliang Sun
- Jing Guo
- Changan Yu
- Yong Wang
- Wei Kong
- Jingang Zheng
View Affiliations

Affiliations: Department of Cardiology, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Biomedical Experimental Research, Institute of Clinical Medicine, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Central Laboratory of Cardiovascular Disease, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing 100191, P.R. China
Published online on: June 7, 2018 https://doi.org/10.3892/etm.2018.6258
Pages: 867-873
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Naringenin (NGN) is a natural flavonoid that exerts antiinflammatory, antioxidant and cardioprotective effects. The present study investigated the effects of NGN on left ventricular hypertrophy in rats with NG‑nitro‑L‑arginine methyl ester (L‑NAME)‑induced hypertension, and sought to determine the underlying mechanism of action. The rats received the following by gavage daily for 56 days: L‑NAME (50 mg/kg/day) + NGN (100 mg/kg/day), L‑NAME (50 mg/kg/day) + saline, or saline + saline. Blood pressure, heart rate and body weight were recorded. Left ventricular hypertrophy was assessed by echocardiography and hematoxylin‑eosin staining. Angiotensin II (Ang II) and angiotensin‑converting enzyme 1 (ACE1), which serve a pivotal role in cardiac remodeling, were evaluated by ELISA, reverse transcription‑quantitative polymerase chain reaction and western blot analysis. NGN had no significant effect on body weight, heart rate or blood pressure. The extent of left ventricular hypertrophy in the L‑NAME + NGN group was lower than in the L‑NAME + saline group on day 56. NGN decreased Ang II and ACE1 protein levels in myocardial tissues. In conclusion, Ang II and ACE1 expression in cardiac tissue was inhibited by NGN in L‑NAME‑treated rats, which may contribute to the inhibitory effects of NGN on left ventricular hypertrophy that is induced by pressure overload.

View Figures

View References

1	Boonpeng H and Yusoff K: The utility of copy number variation (CNV) in studies of hypertension-related left ventricular hypertrophy (LVH): Rationale, potential and challenges. Mol Cytogenet. 6:82013. View Article : Google Scholar : PubMed/NCBI
2	Nayor M, Enserro DM, Vasan RS and Xanthakis V: Cardiovascular health status and incidence of heart failure in the framingham offspring study. Circ Heart Fail. 9:e0024162016. View Article : Google Scholar : PubMed/NCBI
3	Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI and Mendelsohn AO: Localization of angiotensin converting enzyme in rat heart. Circ Res. 68:141–149. 1991. View Article : Google Scholar : PubMed/NCBI
4	Hirsch AT, Talsness CE, Schunkert H, Paul M and Dzau VJ: Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 69:475–482. 1991. View Article : Google Scholar : PubMed/NCBI
5	Borghi C; SIIA Task Force and Rossi F; SIF Task Force, : Role of the renin-angiotensin-aldosterone system and its pharmacological inhibitors in cardiovascular diseases: Complex and critical issues. High Blood Press Cardiovasc Prev. 22:429–444. 2015. View Article : Google Scholar : PubMed/NCBI
6	Hellawell JL and Margulies KB: Myocardial reverse remodeling. Cardiovasc Ther. 30:172–181. 2012. View Article : Google Scholar : PubMed/NCBI
7	Lu Y, Zhang C, Bucheli P and Wei D: Citrus flavonoids in fruit and traditional Chinese medicinal food ingredients in China. Plant Foods Hum Nutr. 61:57–65. 2006. View Article : Google Scholar : PubMed/NCBI
8	Mulvihill EE, Burke AC and Huff MW: Citrus flavonoids as regulators of lipoprotein metabolism and atherosclerosis. Annu Rev Nutr. 36:275–299. 2016. View Article : Google Scholar : PubMed/NCBI
9	Testai L, Martelli A, Cristofaro M, Breschi MC and Calderone V: Cardioprotective effects of different flavonoids against myocardial ischaemia/reperfusion injury in Langendorff-perfused rat hearts. J Pharm Pharmacol. 65:750–756. 2013. View Article : Google Scholar : PubMed/NCBI
10	Subburaman S, Ganesan K and Ramachandran M: Protective role of naringenin against doxorubicin-induced cardiotoxicity in a rat model: Histopathology and mRNA expression profile studies. J Environ Pathol Toxicol Oncol. 33:363–376. 2014. View Article : Google Scholar : PubMed/NCBI
11	Liu X, Wang N, Fan S, Zheng X, Yang Y, Zhu Y, Lu Y, Chen Q, Zhou H and Zheng J: The citrus flavonoid naringenin confers protection in a murine endotoxaemia model through AMPK-ATF3-dependent negative regulation of the TLR4 signalling pathway. Sci Rep. 6:397352016. View Article : Google Scholar : PubMed/NCBI
12	Wang K, Chen Z, Huang L, Meng B, Zhou X, Wen X and Ren D: Naringenin reduces oxidative stress and improves mitochondrial dysfunction via activation of the Nrf2/ARE signaling pathway in neurons. Int J Mol Med. 40:1582–1590. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ren B, Qin W, Wu F, Wang S, Pan C, Wang L, Zeng B, Ma S and Liang J: Apigenin and naringenin regulate glucose and lipid metabolism, and ameliorate vascular dysfunction in type 2 diabetic rats. Eur J Pharmacol. 773:13–23. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zaragozá C, Monserrat J, Mantecón C, Villaescusa L, Zaragozá F and Álvarez-Mon M: Antiplatelet activity of flavonoid and coumarin drugs. Vascul Pharmacol. 87:139–149. 2016. View Article : Google Scholar : PubMed/NCBI
15	Alam MA, Kauter K and Brown L: Naringin improves diet-induced cardiovascular dysfunction and obesity in high carbohydrate, high fat diet-fed rats. Nutrients. 5:637–650. 2013. View Article : Google Scholar : PubMed/NCBI
16	Samak M, Fatullayev J, Sabashnikov A, Zeriouh M, Schmack B, Farag M, Popov AF, Dohmen PM, Choi YH, Wahlers T and Weymann A: Cardiac hypertrophy: An introduction to molecular and cellular basis. Med Sci Monit Basic Res. 22:75–79. 2016. View Article : Google Scholar : PubMed/NCBI
17	Gerdts E, Okin PM, Boman K, Wachtell K, Nieminen MS, Dahlöf B and Devereux RB: Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. Am J Hypertens. 25:678–683. 2012. View Article : Google Scholar : PubMed/NCBI
18	Aronow WS, Ahn C, Kronzon I and Koenigsberg M: Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 67:295–299. 1991. View Article : Google Scholar : PubMed/NCBI
19	Zhu YC, Zhu YZ, Gohlke P, Stauss HM and Unger T: Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol. 80:110A–117A. 1997. View Article : Google Scholar : PubMed/NCBI
20	Zhang N, Yang Z, Yuan Y, Li F, Liu Y, Ma Z, Liao H, Bian Z, Zhang Y, Zhou H, et al: Naringenin attenuates pressure overload-induced cardiac hypertrophy. Exp Ther Med. 10:2206–2212. 2015. View Article : Google Scholar : PubMed/NCBI